WCN26-2146 PROTECT POST HOC ANALYSIS: EFFICACY OF SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IgA NEPHROPATHY ≤12 MO VS >12 MO FROM KIDNEY BIOPSY
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Fields of Study & Subjects
Publication details
- Journal / source
- Kidney International Reports
- Volume
- 11
- Issue
- 4
- Pages
- 105717–105717
- Publication date
- 25 March 2026
- Language
- EN